Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2018-01-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/17460441.2018.1398732PMID 29088927
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matrix Metalloproteinase

  2020cited by this paper
• An unusual spinaceamine-bearing pregnane from a soft coral Scleronephthya sp. inhibits the migration of tumor cells.

  2017cited by this paper
• Fragment‐Based Discovery of 5‐Arylisatin‐Based Inhibitors of Matrix Metalloproteinases 2 and 13

  2016cited by this paper
• Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.

  2016cited by this paper
• Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.

  2016cited by this paper
• Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.

  2016influential reference
• Potential Anti-metastasis Natural Compounds for Lung Cancer.

  2016cited by this paper
• N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.

  2015cited by this paper
• Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.

  2015cited by this paper
• Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.

  2015cited by this paper
• Moving targets: Emerging roles for MMPs in cancer progression and metastasis.

  2015cited by this paper
• Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family.

  2015cited by this paper
• Cancer metastases: challenges and opportunities

  2015cited by this paper
• Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.

  2015cited by this paper
• Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis

  2015cited by this paper
• New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.

  2015cited by this paper
• Therapeutics Targeting Matrix Metalloproteinases

  2015cited by this paper
• Design, synthesis, evaluation and 3D-QSAR analysis of benzosulfonamide benzenesulfonates as potent and selective inhibitors of MMP-2

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• An Integrated Computational and Experimental Approach to Gaining Selectivity for MMP‐2 within the Gelatinase Subfamily

  2014cited by this paper
• Matrix metalloproteinase‐9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: A pilot study in mice

  2014cited by this paper
• Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.

  2014cited by this paper
• Remodelling the extracellular matrix in development and disease

  2014cited by this paper
• Sulphonamide 1,4-dithia-7-azaspiro[4,4]nonane derivatives as gelatinase A inhibitors.

  2013cited by this paper
• Probing the S1′ Site for the Identification of Non‐Zinc‐Binding MMP‐2 Inhibitors

  2013cited by this paper
• Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.

  2013cited by this paper
• Tumor metastasis: moving new biological insights into the clinic

  2013cited by this paper
• Missing the target: matrix metalloproteinase antitargets in inflammation and cancer.

  2013cited by this paper
• Targeting tumor cell motility as a strategy against invasion and metastasis.

  2013cited by this paper
• Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.

  2013cited by this paper
• Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.

  2013cited by this paper
• MMP inhibition by barbiturate homodimers.

  2013cited by this paper
• Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis

  2013cited by this paper
• On the origin of cancer metastasis.

  2013cited by this paper
• O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.

  2013cited by this paper
• Progress towards water-soluble triazole-based selective MMP-2 inhibitors.

  2013influential reference
• In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.

  2012cited by this paper
• MMP-2 selectivity in hydroxamate-type inhibitors.

  2012cited by this paper
• Specificity of binding with matrix metalloproteinases.

  2012cited by this paper
• Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential

  2012cited by this paper
• Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.

  2012cited by this paper
• Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.

  2012cited by this paper
• Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.

  2012influential reference
• Natural products as a gold mine for selective matrix metalloproteinases inhibitors.

  2012cited by this paper
• Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.

  2012cited by this paper
• Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.

  2012cited by this paper
• Biphenyl Sulfonylamino Methyl Bisphosphonic Acids as Inhibitors of Matrix Metalloproteinases and Bone Resorption

  2011influential reference
• Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential

  2011cited by this paper
• Structural Basis for Matrix Metalloproteinase-2 (MMP-2)-selective Inhibitory Action of β-Amyloid Precursor Protein-derived Inhibitor*

  2011cited by this paper
• Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.

  2011cited by this paper
• Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.

  2011cited by this paper
• N-substituted homopiperazine barbiturates as gelatinase inhibitors.

  2011cited by this paper
• Synthesis and anticancer activities of ageladine A and structural analogs.

  2010cited by this paper
• Anti-invasive and anti-angiogenic activities of naturally occurring dibenzodiazepine BU-4664L and its derivatives.

  2010cited by this paper
• Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression.

  2010cited by this paper
• Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I).

  2010cited by this paper
• Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.

  2010cited by this paper
• The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function.

  2010cited by this paper
• Matrix metalloproteinases: regulators of the tumor microenvironment.

  2010cited by this paper
• Fluorine and Health Molecular Imaging, Biomedical Materials and Pharmaceuticals, first ed., A. Tressaud, G. Haufe (Eds.). Elsevier (2008), +792 pp., ISBN: 978-0-444-53086-8

  2009cited by this paper
• Synthesis and evaluation of myxochelin analogues as antimetastatic agents.

  2009cited by this paper
• Active Site Ring‐Opening of a Thiirane Moiety and Picomolar Inhibition of Gelatinases

  2009cited by this paper
• Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.

  2009cited by this paper
• Selective matrix metalloproteinase inhibitors for cancer.

  2009cited by this paper
• Progress in the development of matrix metalloproteinase inhibitors.

  2008cited by this paper
• Matrix metalloproteinase inhibitors as anticancer agents.

  2008cited by this paper
• Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.

  2008cited by this paper
• Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.

  2008cited by this paper
• The other side of MMPs: Protective roles in tumor progression

  2007cited by this paper
• Matrix metalloproteinases and the regulation of tissue remodelling

  2007cited by this paper
• 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents.

  2007cited by this paper
• Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

  2006cited by this paper
• Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.

  2006cited by this paper
• Recent advances in MMP inhibitor design

  2006influential reference
• Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy

  2006cited by this paper
• Matrix metalloproteinase inhibitors as anticancer therapeutics.

  2005cited by this paper
• Hydroxamic acid derivatives as metalloproteinase inhibitors

  2004cited by this paper
• A High Serum Matrix Metalloproteinase-2 Level Is Associated with an Adverse Prognosis in Node-Positive Breast Carcinoma

  2004cited by this paper
• Ageladine A: an antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai.

  2003cited by this paper
• Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects

  2003cited by this paper
• Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.

  2003cited by this paper
• Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.

  2003cited by this paper
• Gelatinases A and B.

  2002cited by this paper
• Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.

  2002cited by this paper
• Strategies for MMP inhibition in cancer: innovations for the post-trial era

  2002cited by this paper
• Development of matrix metalloproteinase inhibitors in cancer therapy.

  2001cited by this paper
• Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

  2001cited by this paper
• Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.

  2001cited by this paper
• Final results of a double-blind placebo-controlled study of adjuvant marimastat in small cell lung cancer (SCLC) patients responding to standard therapy

  2001cited by this paper
• Serum levels of matrix metalloproteinase 2 in patients with breast cancer.

  2001cited by this paper
• Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.

  2001cited by this paper
• Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999).

  2001cited by this paper
• Potent and Selective Mechanism-Based Inhibition of Gelatinases

  2000cited by this paper
• Determination of matrix metalloproteinase activity using biotinylated gelatin.

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).

  2000cited by this paper
• [Matrix metalloproteinase inhibitors].

  2000cited by this paper
• Design and therapeutic application of matrix metalloproteinase inhibitors.

  1999cited by this paper
• Tumor targeting with a selective gelatinase inhibitor

  1999cited by this paper
• MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

  1999cited by this paper

• A Comprehensive Analysis of the Clinical Significance and Underlying Oncogenic Roles of Specific MMPs in Gastric Carcinoma Reveals their Potential Roles in Prognosis and Therapy.

  2025cites this paper
• The potential of miR-29 in modulating tumor angiogenesis: a comprehensive review

  2025cites this paper
• Identifying functional roles and pathways of shared mutations in canine solid tumors by whole-genome sequencing

  2025cites this paper
• Does chlorotoxin target matrix metalloproteinase-2 in glioblastoma?

  2025cites this paper
• Intelligent delivery and clinical transformation of nanomedicine in breast cancer: from basic research to individualized therapy

  2025cites this paper
• Prognostic value of matrix metalloproteinase-2 protein and matrix metalloproteinase-9 protein in colorectal cancer: a meta-analysis

  2024cites this paper
• Expression, purification and refolding of pro-MMP-2 from inclusion bodies of E. coli.

  2023cites this paper
• Wilms’ tumour gene 1 (WT1) enhances non-small cell lung cancer malignancy and is inhibited by microRNA-498-5p

  2023cites this paper
• Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013–2023)

  2023cites this paper
• Diagnostic, Prognostic, and Therapeutic Role for Angiogenesis Markers in Head and Neck Squamous Cell Carcinoma: A Narrative Review

  2023cites this paper
• Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1

  2023cites this paper
• Influence of N-arylsulfonamido d-valine N-substituents on the selectivity and potency of matrix metalloproteinase inhibitors.

  2023cites this paper
• A cheminformatics-biophysics correlate to identify promising lead molecules against matrix metalloproteinase-2 (MMP-2) enzyme: A promising anti-cancer target

  2023cites this paper
• Psoriasis ve Psoriatik Artrit Hastalarında ADAMTS9 ve ADAMTS15 mRNA Ekspresyon Düzeylerinin Araştırılması

  2023cites this paper
• Proteoglycan SPOCK1 as a Poor Prognostic Marker Promotes Malignant Progression of Clear Cell Renal Cell Carcinoma via Triggering the Snail/Slug-MMP-2 Axis-Mediated Epithelial-to-Mesenchymal Transition

  2023influential citation
• Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.

  2022cites this paper
• Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis

  2022cites this paper
• Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents

  2022cites this paper
• A fragment-based structural analysis of MMP-2 inhibitors in search of meaningful structural fragments

  2022cites this paper
• Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

  2022influential citation
• Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance.

  2022cites this paper
• A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors

  2022cites this paper
• Current Perspectives on the Role of Matrix Metalloproteinases in the Pathogenesis of Basal Cell Carcinoma

  2021cites this paper
• Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway

  2021cites this paper
• Asymmetric polymersomes, from the formation of asymmetric membranes to the application on drug delivery.

  2021cites this paper
• Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.

  2021cites this paper
• Het(aryl)isatin to het(aryl)aminoindoline scaffold hopping: a route to selective inhibitors of matrix metalloproteases

  2021cites this paper
• Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation

  2021cites this paper
• Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting

  2021cites this paper
• The Repression of Matrix Metalloproteinases and Cytokine Secretion in Glioblastoma by Targeting K+ Channel

  2021cites this paper
• RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR/AKT signaling pathway

  2021cites this paper
• The Search for Natural and Synthetic Inhibitors That Would Complement Antivenoms as Therapeutics for Snakebite Envenoming

  2021cites this paper
• MiR‐95‐5p involves in the migration and invasion of trophoblast cells by targeting low density lipoprotein receptor‐related protein 6

  2020cites this paper
• Inhibition of Matrix Metalloproteinase-2 modulates malignant behaviour of oral squamous cell carcinoma cells.

  2020cites this paper
• Bacillus pumilus Ribonuclease Inhibits Migration of Human Duodenum Adenocarcinoma HuTu 80 Cells

  2020cites this paper
• Clinical role of MiRNA 29a and MiRNA 335 on breast cancer management: their relevance to MMP2 protein level

  2020cites this paper
• [Bacillus pumilus Ribonuclease Inhibits Migration of Human Duodenum Adenocarcinoma HuTu 80 Cells].

  2020cites this paper
• Th17 lymphocyte‐dependent degradation of joint cartilage by synovial fibroblasts in a humanized mouse model of arthritis and reversal by secukinumab

  2020cites this paper
• Matrix metalloproteinases (MMPs) in targeted drug delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix metalloproteinases-7.

  2020cites this paper
• Selected Matrix Metalloproteinases (MMP-2, MMP-7) and Their Inhibitor (TIMP-2) in Adult and Pediatric Cancer

  2020cites this paper
• The MMP-2/TIMP-2 system in Alzheimer disease.

  2020cites this paper
• Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review

  2020cites this paper
• Challenges with matrix metalloproteinase inhibition and future drug discovery avenues

  2020cites this paper
• Different roles of matrix metalloproteinase 2 in osteolysis of skeletal dysplasia and bone metastasis

  2020cites this paper
• Anti-pulmonary metastases from cervical cancer responses induced by a human papillomavirus peptide vaccine adjuvanted with CpG-oligodeoxynucleotides in vivo.

  2020cites this paper
• Prognostic role of matrix metalloproteinase 9 in early breast cancer

  2020cites this paper
• A nanometer-sized protease inhibitor for precise cancer diagnosis and treatment.

  2019cites this paper
• Synergistic Beneficial Effect of Docosahexaenoic Acid (DHA) and Docetaxel on the Expression Level of Matrix Metalloproteinase-2 (MMP-2) and MicroRNA-106b in Gastric Cancer

  2019cites this paper
• Circ_KATNAL1 regulates prostate cancer cell growth and invasion through miR-145-3p/WISP1 pathway

  2019cites this paper
• Pathological and therapeutic aspects of matrix metalloproteinases: implications in childhood leukemia

  2019cites this paper
• Circ_KATNAL1 regulates prostate cancer cell growth and invasion through miR-145-3p/WISP1 pathway.

  2019cites this paper
• Recent insights into natural product inhibitors of matrix metalloproteinases.

  2019cites this paper
• Novel Matrix Metalloproteinase 12 selective radiotracers for vascular molecular imaging.

  2019cites this paper
• Extracellular Matrix Alterations in Metastatic Processes

  2019cites this paper
• Progress in Research on Tumor Metastasis Inhibitors.

  2019cites this paper
• Updating the role of matrix metalloproteinases in mineralized tissue and related diseases

  2019cites this paper
• MMP2 as an independent prognostic stratifier in oral cavity cancers

  2019cites this paper
• The E2F3/miR-125a/DKK3 regulatory axis promotes the development and progression of gastric cancer

  2019cites this paper
• Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation

  2019cites this paper
• CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion

  2019cites this paper
• A DSTYK mutation activates ERK1/2 signaling to promote intraspinal dissemination in a case of solitary fibrous tumor/hemangiopericytoma

  2019cites this paper
• Search for drug discovery targets focusing on cancer stroma

  2019cites this paper
• Inhibition of MMPs and ADAM/ADAMTS.

  2019cites this paper
• Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.

  2019cites this paper
• 1 Amino Acids as Building Blocks for Carbonic 2 Anhydrase Inhibitors 3

  2018cites this paper
• Synthesis and PreliminaryIn VitroandIn VivoEvaluation of Thiirane‐Based Slow‐Binding MMP Inhibitors as Potential Radiotracers for PET Imaging

  2018cites this paper
• A Systematic Review of miR-29 in Cancer

  2018cites this paper
• Vitamin D status and its management for achieving optimal health benefits in the elderly

  2018cites this paper
• Identification of MMP9 as a novel key gene in mantle cell lymphoma based on bioinformatic analysis and design of cyclic peptides as MMP9 inhibitors based on molecular docking

  2018influential citation
• Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid

  2018cites this paper
• RNA interference screening identifies clathrin‐B and cofilin‐1 as mediators of MT1‐MMP in endometrial cancer

  2018cites this paper
• Amino Acids as Building Blocks for Carbonic Anhydrase Inhibitors

  2018cites this paper
• Proteolysis to Identify Protease Substrates: Cleave to Decipher

  2018cites this paper